Updated from Friday, Oct. 10
Third-quarter results that will begin to roll in from biotech companies Tuesday have taken on new importance, as investors look to see if drug stocks will be a safe haven in the panic-stricken market. Large-cap names are expected to perform at least in line with expectations, with some showing upside despite seasonality and pushback from a strengthening dollar.
Stock |
Date |
3Q EPS Consensus |
3Q Rev Consensus |
FY08 EPS Consensus |
FY08 Rev Consensus |
DNA |
10/14 |
88 cents |
$3.36B |
$3.45 |
$13.14B |
GILD |
10/16 |
49 cents |
$1.32B |
$1.98 |
$5.25B |
BIIB |
10/21 |
89 cents |
$1B |
$3.55 |
$3.98B |
GENZ |
10/22 |
$1 |
$1.18B |
$3.95 |
$4.65B |
AMGN |
10/22 |
$1.08 |
$3.7B |
$4.37 |
$14.82B |
CELG |
10/23 |
39 cents |
$592M |
$1.54 |
$2.26B |
| Source: Thomson First Call | |||||
Genentech, Oct. 14
Analysts expect Genentech to earn 88 cents a share, on revenue of $3.36 billion. However, investors will likely focus on the potential buyout by Roche. The biotech bellwether in July rejected a bid from Swiss pharma company, which has yet to respond.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |














